Vital Mind Functional Medicine

07/26/2026

How the Intellxx genetics report has helped me and will help our patients.

07/25/2026

Live from Intelxx.

02/10/2026

At one time, I thought red light therapy for treating cogtitive decline was snake oil. But, my patients are seeing benefits and studies are showing red light therapy reduces inflammation, decreases plaque, and boosts BDNF (brain fertilizer). Of course these are "preliminary studies." But many of our patients are reporting benefits. This is the recommended company and they have a 90 day free trial.

Learn how PBM and Neuronic support Alzheimer’s disease care by targeting brain energy, cognition, and mitochondrial function.

12/31/2025

This is a "hot off the press" report on a clinical trial done to improve Alzheimer's using "precision medicine." Precision Medicine is looking at an individuals biomarkers- and prioritizing interventions, mostly lifestyle, for improving cognition. The results are clearly better than the "best" medical therapy we have (Lecanemab). These are the assessments and interventions we use at Vital Mind and I am fortunate to be mentored by several of the authors. The best advice I heard at this month's town hall, is "don't wait." Gains are best seen early on in the disease process, when you have subjective or mild cognitive impairment.

Happy New Year to all, and I hope that everyone is enjoying time with loved ones. Meanwhile, we have very exciting results from our randomized controlled trial, and these have just been posted as a preprint: https://www.preprints.org/frontend/manuscript/8118568f183e2ba91ec2a1d3b3d08fb9/download_pub . These results will be submitted for peer review in February; here is a summary of some of the key findings:

(1) Our protocol produced statistically significant improvements in memory, executive function, brain processing speed, and overall cognition, whereas the standard of care treatment did not;
(2) cognitive symptoms were markedly improved by our protocol, as noted both by the patients and their partners;
(3) statistically significant improvements in multiple health parameters occurred with our protocol: better blood pressure, body mass index, insulin sensitivity, hemoglobin A1c, lipid profiles (“cholesterol”), and methylation.
(4) The overall effect of our protocol was greater than any other treatment for cognitive decline—and 600% better (i.e., 7 times) the effect of Leqembi, the Alzheimer’s drug (you can see this in Figure 10 in the preprint).

Here’s to continued great progress in 2026—let’s all work together to reduce the global burden of dementia. We can do it.

11/30/2025

Are you noticing a sudden wave of headlines claiming a single supplement, enzyme, or molecule “reverses Alzheimer’s”?
Before you jump on the bandwagon, here’s the part those articles don’t mention:

Most of these studies are done in mice genetically engineered to act like they have Alzheimer’s. That’s not the same thing as the real, messy, human condition.

And here’s the kicker: a recent study (linked in comments) compared clinical diagnoses with post-mortem brain analysis and found that only 7% of people diagnosed with dementia had pure Alzheimer’s pathology—the classic plaques and tangles without anything else going on.

Only seven percent.

This just reinforces what many of us in brain health have been saying for years:
The disease we casually call “Alzheimer’s” is usually a mixed picture with multiple root causes—not a single, simple condition with a single, simple fix.

So stay curious, stay cautious, and always look beyond the headline.